Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc bought 204,098 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were acquired at an average price of $13.13 per share, for a total transaction of $2,679,806.74. Following the completion of the transaction, the director now directly owns 15,411,078 shares in the company, valued at approximately $202,347,454.14. This represents a 1.34 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 8th, Ecor1 Capital, Llc acquired 21,021 shares of Zymeworks stock. The shares were bought at an average cost of $14.07 per share, for a total transaction of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc acquired 157,880 shares of Zymeworks stock. The stock was bought at an average cost of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc bought 58,988 shares of Zymeworks stock. The shares were bought at an average cost of $14.47 per share, for a total transaction of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock. The shares were purchased at an average cost of $14.12 per share, with a total value of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc bought 16,692 shares of Zymeworks stock. The stock was purchased at an average cost of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Stock Performance

NYSE ZYME traded down $0.91 on Friday, reaching $13.22. 798,973 shares of the stock traded hands, compared to its average volume of 594,729. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The company has a market cap of $910.57 million, a price-to-earnings ratio of -8.81 and a beta of 1.10. The company has a fifty day moving average price of $14.48 and a 200-day moving average price of $12.39.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The firm had revenue of $16.00 million during the quarter, compared to the consensus estimate of $17.90 million. During the same period in the previous year, the company posted ($0.41) earnings per share. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. As a group, research analysts anticipate that Zymeworks Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ZYME shares. HC Wainwright reiterated a “neutral” rating and set a $12.00 price target on shares of Zymeworks in a report on Friday, November 22nd. Leerink Partners raised Zymeworks from a “market perform” rating to an “outperform” rating and upped their target price for the company from $10.00 to $25.00 in a research note on Thursday, November 7th. Leerink Partnrs raised Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Citigroup upped their price objective on Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price for the company in a research report on Monday, December 16th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.17.

Institutional Investors Weigh In On Zymeworks

Several hedge funds have recently modified their holdings of the business. Barclays PLC lifted its stake in shares of Zymeworks by 476.3% during the 3rd quarter. Barclays PLC now owns 154,384 shares of the company’s stock worth $1,937,000 after purchasing an additional 127,595 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Zymeworks by 27.3% during the third quarter. Jane Street Group LLC now owns 80,326 shares of the company’s stock valued at $1,008,000 after buying an additional 17,205 shares during the last quarter. State Street Corp lifted its position in shares of Zymeworks by 6.1% during the third quarter. State Street Corp now owns 1,171,777 shares of the company’s stock valued at $14,706,000 after buying an additional 67,401 shares during the last quarter. Stifel Financial Corp boosted its holdings in shares of Zymeworks by 2.1% in the 3rd quarter. Stifel Financial Corp now owns 73,654 shares of the company’s stock valued at $924,000 after buying an additional 1,540 shares in the last quarter. Finally, Vestal Point Capital LP grew its position in shares of Zymeworks by 39.8% in the 3rd quarter. Vestal Point Capital LP now owns 615,000 shares of the company’s stock worth $7,718,000 after buying an additional 175,000 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.